Discover the potential impact of point-of-care single-molecule proteomics in enabling precision medicine, reshaping our approach to healthcare, and how current research on solid-state nanopores is bringing us closer to realizing this potential.
When: September 26th, 2023 at 11 am EST.
You will learn:
Explore various specific examples of how single-molecule, point-of-care proteomics could potentially impact drug trials and acute hospital care.
A brief overview of the health economics involved in designing effective interventions in precision medicine
How current research in solid-state nanopores is tackling the remaining challenges to realizing this potential.
Who should attend:
Solid-state nanopore researchers
Anyone interested in precision medicine
Kyle Briggs, PhD is the CEO of Northern Nanopore. He has more than 10 years of experience in solid-state nanopore research, with 18 papers and 5 patents. He is a Vanier Scholar and has received numerous awards for his research accomplishments. He is the primary coder behind Nanolyzer.
Matthew Waugh, MSc MBA, is the COO of Northern Nanopore and is responsible for all of our instrumentation development and customer support. He has 10 years of experience in solid-state nanopore research and many publications.
Learn more about nanopore fabrication by controlled breakdown
Learn more about research tools for nanopore fabrication
Chat with the experts directly